Page 2 - Rating Scale News Today

Children and adults with ADHD show greater improvement in symptoms with viloxazine extended release compared with treatment with atomoxetine, new research suggests.

A four-week course of ketamine injections may be effective against treatment-resistant depression, a double-blind trial shows.

Subcutaneous ketamine is a practical, safe, and highly effective way to administer the drug for treatment-resistant depression, results of a randomized controlled phase 3 trial show.

Experts have developed a new seven-point rating scale for diagnosing Alzheimers disease based on cognitive and biological changes in patients. The proposed guidelines replace those issued in 2018 and embrace a numerical staging system similar to that used in cancer diagnoses, with stages 1-7 based on the presence of abnormal disease biomarkers and changes in cognitive ability.

Effective when given as a flexible dose twice-weekly

Few validated measures exist to quantify sleep disturbance among patients who have the chronic inflammatory skin condition prurigo nodularis.

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week...

After a series of milestone approvals in the first half of 2023, the FDA is slated to decide on four more firsts before the year’s end.

Certain polyunsaturated fatty acids (PUFAs) may have a favorable effect on disease progression and survival for patients with amyotrophic lateral sclerosis.

Physiologic responses of therapists as measured by oxytocin levels may play a role in therapeutic outcomes in patients with depression.